跳至主要内容
临床试验/CTIS2024-511388-27-04
CTIS2024-511388-27-04招募中1 期

Add-on Clioquinol in drug-resistant epilepsy: an exploratory study - CLIOKIDA

Z Leuven0 个研究点目标入组 20 人开始时间: 2024年7月8日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
0 至 64(—)
性别
All

入选标准

  • Drug-resistant epilepsy: = 4 seizures in the 2 week prospective period (baseline) before visit 2, not all (4) seizures observed in 1 of the 2 weeks. Baseline period can be extended with 1 or 2 weeks., Age = 12 years and < 35 years at time of inclusion, Drug-resistant epilepsy: before inclusion failure of at least 2 AEDs, The patient is at the moment of inclusion on max 3 anti-epileptic drugs (VNS and ketogenic diet not included), Well defined epilepsy history with convulsive seizures (with observable and countable motor component)

排除标准

  • Presence of C609T NQO1 SNP after SNP analysis of NQO1 based on a blood sample during baseline visit (visit 1) by Genomics Core, Asian etnicity, Abnormal low blood level of vitamin B12 or Zn

研究者

发起方
Z Leuven

相似试验